A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer; Camrelizumab Interventions: Drug: Camrelizumab + chemotherapy+Thalidomide; Drug: Camrelizumab + chemotherapy+placebo Sponsors: Tongji University; Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study